Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical development for the treatment of schizophrenia. Ulotaront was discovered through a unique, target-agnostic approach optimized to identify drug candidates lacking D2 and 5-HT2A receptor antagonism, while demonstratin...

Descripción completa

Detalles Bibliográficos
Autores principales: Achtyes, Eric D., Hopkins, Seth C., Dedic, Nina, Dworak, Heather, Zeni, Courtney, Koblan, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Invited Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465394/
https://www.ncbi.nlm.nih.gov/pubmed/37165101
http://dx.doi.org/10.1007/s00406-023-01580-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465394/
https://www.ncbi.nlm.nih.gov/pubmed/37165101
http://dx.doi.org/10.1007/s00406-023-01580-3

Ejemplares similares